8.730USD+16.25%Mkt Cap: —P/E: —1d ago
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other so…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value3.66B $
Revenue (TTM)324.97M $
Gross Profit157.29M $
Net Income (TTM)-289.52M $
Revenue/Share0.7920 USD
Last Price8.730 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees975
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-14.11
EV/Revenue11.27
P/S—
P/B5.45
EPS (TTM)-2.30
EPS (Forward)—
52W Range
6.50097% of range8.800
52W High8.800 USD
52W Low6.500 USD
Profitability
Gross Margin48.40%
Oper. Margin-52.26%
EBITDA Margin-79.88%
Profit Margin-89.09%
ROE-40.36%
ROA-20.31%
Growth
Revenue Growth65.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-264.18M $
CapEx (TTM)—
FCF Margin-57.79%
FCF Yield—
Net Debt-251.67M $
Net Debt/EBITDA0.97
Balance Sheet
Debt/Equity6.25
Current Ratio4.34
Quick Ratio3.74
Book Value/Sh1.625 USD
Cash/Share0.6570 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.123.17M
Float394.36M
Insiders0.34%
Institutions70.49%
Technical
SMA 5011.04 (-20.9%)
SMA 2007.438 (+17.4%)
Beta0.70
S&P 52W Chg18.16%
Avg Vol (30d)172.11K
Avg Vol (10d)29.45K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—